ATG 022
Alternative Names: ATG-022; ATN-022Latest Information Update: 02 Jun 2025
At a glance
- Originator Antengene Corporation
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 20 May 2025 Antengene Corporation and Merck Sharp & Dohme collaborates for clinical trial for Solid tumurs
- 23 Jan 2025 Efficacy, pharmacokinetics and adverse events data from phase I CLINCH trial in Gastric cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GI-2025)
- 22 Jan 2025 Efficacy and adverse events data from phase I/II CLINCH trial in Solid tumours released by Antennova